"Pharmaceutical-themed funds have turned adversity into success, and institutions are seizing the opportunity to strategically deploy their investments."

After a long silence, the innovative pharmaceutical sector has reached a turning point, driving the performance of healthcare-related funds to skyrocket, with over 50% returns for many funds this year. The profit-making effect of the pharmaceutical sector is significant, attracting institutional layouts. Recently, many new funds have been established, and long-term funds are also entering the market one after another, causing a sudden increase in investment heat in the pharmaceutical sector. Industry insiders believe that innovative pharmaceutical companies actively going global, the unstoppable momentum of industry upgrading, and the future investment opportunities are promising. According to Choice data, as of May 30th, a total of 18 actively managed equity funds have gained over 50% returns this year, including 12 that are heavily invested in the innovative pharmaceutical sector.